NCT03424252View on ClinicalTrials.gov

An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions

Cystic Fibrosis

Interventions

DRUG

FDL169

Cystic Fibrosis Transmembrane Regulator (CFTR) corrector

Trial Locations (1)

NG116JS

Quotient Sciences, Nottingham

All Listed Sponsors

lead

Flatley Discovery Lab LLC

OTHER

NCT03424252 - An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects | Biotech Hunter | Biotech Hunter